• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Expert Reviews Findings From the AURIGA Study in Myeloma

by | Sep 27, 2024 | Myeloma News

Source: Pharmacy Times articles Ashraf Badros, MBCHB, discussed findings from the AURIGA study being presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil. Read More

Immunotherapy Advancements Pave the Way for Enhanced Multiple Myeloma Treatment

by | Sep 26, 2024 | Myeloma News

Source: Pharmacy Times articles Experts discuss current knowledge and future indications for immunotherapies and CAR T in early treatment lines. Read More

T Cell-Directed Therapies Are Rapidly Expanding for Myeloma

by | Sep 26, 2024 | Myeloma News

Source: Pharmacy Times articles Banerjee addressed factors to consider when selecting a regimen, the available treatments in this category, and their key differences. Read More

Factors to Consider When Selecting T Cell-Directed Therapies for Myeloma

by | Sep 26, 2024 | Myeloma News

Source: Pharmacy Times articles Rahul Banerjee, MD, FACP, discussed his presentation at the International Myeloma Society 2024 Annual Meeting on available T cell-directed therapies for myeloma treatment, including CAR T-cell therapies and bispecific antibodies. Read...

Leveraging AI for More Accurate Multiple Myeloma Predictions

by | Sep 25, 2024 | Myeloma News

Source: Pharmacy Times articles Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma. Read More

Multiple Myeloma Precursor Diseases: Advancing Diagnosis and Treatment for MGUS and SMM

by | Sep 25, 2024 | Myeloma News

Source: Pharmacy Times articles Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression. Read More
« Older Entries
Next Entries »

Recent Content

  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT